June 3, 2008 - Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer and is as sensitive as MRI for most cancers, according to an article in the June issue of Radiology.

In the study, completed by The George Washington University Medical Center in Washington, D.C., 146 women underwent BSGI and breast biopsy. Study images were assigned scores, and scores were classified as positive or negative and compared with biopsy results. BSGI helped detect cancer in 96.4 percent of the noted malignant lesions; the positive predictive value was 68.8 percent, specificity of 59.5 percent and the negative predictive value for nonmalignant lesions was 94.3 percent. The smallest invasive cancer and DCIS detected were both 1 millimeter, and BSGI helped detect occult cancer not visualized at mammography or ultrasonography in six patients.

Mammography remains the imaging modality of choice for breast cancer screening. The overall sensitivity of mammography has been reported to be 78 to 85 percent; however, the sensitivity of mammography decreases to 42 to 68 percent in women with dense breasts. In addition, the false-positive rate of screening mammography is 15 to 30 percent, leading to many benign findings at biopsy. Limitations in the sensitivity and specificity of screening mammography led to the investigation of adjunct breast Imaging modalities; specifically BSGI, which provides physiological data not obtained with the anatomic Imaging techniques of mammography and ultrasound.

BSGI, molecular imaging of the breast utilizing a high-resolution, small-field-of-view gamma camera, is an increasingly utilized adjunct imaging modality for the diagnosis of breast cancer. Initial studies with this imaging technique report sensitivities similar to MRI with a higher specificity, which is the ability of a test to show when disease is not present.

For more information: www.gwumc.edu


Related Content

News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Artificial Intelligence

June 26, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced it ...

Time June 26, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | Breast Density

June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower ...

Time June 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
News | FDA

May 22, 2024 — The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic Inc. BioZorb marker due to ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
Subscribe Now